Role of Retinol-binding Protein 4 as an Early Biomarker for Diabetic Nephropathy in Type 2 Diabetic Patients

Assess the relationship and diagnostic performance of retinol-binding protein 4 (RBP-4) as a biomarker ofdiabetic nephropathy (DN) at different levels albuminuria (normo-, micro- macro-albuminuria). Acase-control study, that involved 185 participants, 47 were healthy control, 138 diabetic patients (46were normoalbuminuric [NA], 48 microalbuminuria [MiA], 44 weremacroalbuminuria [MaA]). All treated with antidiabetic medication (metformin and/or oral sulfonylureas), all participants interviewed by researcher, full medical (history ofliver, kidney, lung, other diseases), sociodemographic data taken from them recorded in thequestionnaire. In present RBP-4 was 14.08±1.82 ng/ml control group, 15.98±3.74 ng/mlin normoalbuminuria (NA) 30.38±6.02 micro-albuminuria (MiA), 41.01±5.78ng/ml for macro-albuminuria (MaA), there significant difference between their groups comparedto (p-value <0.001), each <0.001) except no differencefound normoalbuminuria. conclusion, RBP4 is an excellent predictor bothmicroalbuminuria microalbuminuria, inverse GFR, whichindicate it good progression kidney impairment.